Dual trigger for final oocyte maturation in expected normal responders with a high immature oocyte rate: a randomized controlled trial.
| Autor: | Yan MH; The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China., Sun ZG; The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China.; Reproductive Center of Integrated Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China., Song JY; The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China.; Reproductive Center of Integrated Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in medicine [Front Med (Lausanne)] 2023 Oct 05; Vol. 10, pp. 1254982. Date of Electronic Publication: 2023 Oct 05 (Print Publication: 2023). |
| DOI: | 10.3389/fmed.2023.1254982 |
| Abstrakt: | Objective: To evaluate whether dual trigger could improve reproductive outcomes in women with low oocyte maturation rates compare to human chorionic gonadotropin (hCG) trigger. Methods: This study included expected normal ovarian responders younger than 40 years old whose immature oocyte rate in the previous cycle was more than 50% at the reproductive center from July 2021 to November 2022. A total of 73 patients were enrolled at trigger, including 34 in the hCG trigger group and 39 in the dual trigger group (co-administration of gonadotrophin releasing hormone (GnRH) agonist and hCG, 40 and 34 h prior to oocyte retrieval, respectively). The primary outcome was oocyte maturation rate. Results: There was no significant difference in the number of oocytes retrieved between the two study groups, but the oocyte maturation rate was higher in dual trigger group (84.0% [14.0%] vs. 55.5% [19.8%], p < 0.001). Moreover, there were also higher cumulative pregnancy rate (69.4% vs. 40.0%, p = 0.035) and cumulative live birth rate (66.7% vs. 36.0%, p = 0.022) in dual trigger group. Conclusion: For normal responders with low oocyte maturation rates, the dual trigger may be more effective than the conventional hCG trigger. Clinical Trial Registration: ClinicalTrials.gov, identifier ChiCTR2100049292. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Yan, Sun and Song.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|